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Table 1
Pre-HCT d180
Partial Response or worse ( PR) 9 9
Very Good Partial Response or
better (VGPR)
10 0
Complete Remission (CR) 3 13
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210S204test (SAS9.3) and Kruskal-Wallis test (non-parametric) were
applied to analyze the data using the Graphpad Software.
Results: The percent NK cell was highest (median: 20% of
total lymphocytes) at d14 (p: 0.0001) compared to pre and
post HCT levels and reached baseline at d 60. The percent NK
cell was higher in VGPR (n¼13) [median: 14.34% (6.29-
28.17) and 16.08 % (7.26-31.19)] compared to PR (n¼9)
[median: 8.17% (4.01- 17.3) and 7.34 %(5.79- 47.8)] respec-
tively at d 90 (p-0.019) and d 180 (p-0.045). The NK cells
expressing CD 16 was 12.2 times higher in patients after
receiving Lenalidomide (n¼18) (p-0.05) compared to pre-
lenalidomide time point.
Conclusion: After auto-HCT, NK cell recovery was reached at
60 days after HCT and was higher in VGPR compared to
PR group at later times. This observation could indicate
enhanced host NK cell immune response against MM.
Lenalidomide therapy increased the percent of NK/ CD 16+
cells that mediates ADCC immune response. Future clinical
trials will explore therapies that increase NK cell cytolytic
responses to MM cancer cells.182
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High-dose, post-transplantation Cy (PT/Cy) is a novel and
effective strategy for preventing graft-versus-host disease
(GVHD) after allogeneic blood or marrow transplantation
(alloBMT). We previously reported that regulatory T cells
(Tregs) are resistant to Cy in allogeneic reactions; activated
Tregs (CD4+CD45RA-Foxp3+hi) are relatively increased 30 and
60 days after PT/Cy in vivo and both naïve (CD4+CD45RA+-
Foxp3+) and activated Tregs are resistant to cytotoxicity
induced by activated Cy (mafosfamide) in mixed lymphocyte
reactions (MLR) in vitro. However, the mechanisms of Treg
resistance to Cy have not been understood. As resistance of
hematopoietic stem cells to Cy is dependent on expression of
the ALDH-1 family (retinaldehyde dehydrogenases), we
hypothesized that Tregs also might express ALDH as a poten-
tial mechanism of resistance to Cy. To examine ALDH
expression, we used Aldeﬂuor as an established and repro-
ducible ﬂow cytometric-based method. There was minimal
to no Aldeﬂuor-positivity in unstimulated Tregs. However,
after allogeneic stimulation in MLR, signiﬁcant subsets of
both naïve and activated Tregs were Aldeﬂuor-positive. These
ﬁndings were conﬁrmed by PCR which showed undetectable
mRNA transcript levels in unstimulated cells but signiﬁcant
upregulation of ALDH1A1 in naïve and activated Tregs at Days
3 and 7 of MLR. These ALDH+ cells persisted after mafosfa-
mide treatment but were not present in signiﬁcant amounts
in the presence of cyclosporine or rapamycin (activated Tregs,
P ¼ .027). ALDH expression correlated with expression of
the activation markers CD69 and CD25 and withproliferation. The clinical relevance of these ﬁndings was
conﬁrmed by showing Aldeﬂuor+CD4+ T cells in peripheral
blood retrieved from patients on Day 3 post-alloBMT at the
time of receiving PT/Cy. To dissect functional implications
of these ﬁndings, we explored pharmacological inhibition
of ALDH using diethylaminobenzaldehyde (DEAB). DEAB
treatment drastically reduced activation and proliferation
of CD4+CD25+ T cells in MLR (P ¼ .031 for both compari-
sons) and abolished Treg resistance to mafosfamide-induced
cytotoxicity (activated Tregs, P < .001). Therefore, resistance
of Tregs to Cy is dependent at least in part on ALDH
expression in allogeneic reactions. Given the role of ALDH
as the rate-limiting step in retinoic acid (RA) biosynthesis
and the crucial contributions of RA to both immune toler-
ance and CD4+ T cell function, pharmacologic manipulation
of this pathway may open a new avenue for modulating
alloreactivity after alloBMT.183
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Reconstitution of immune function in recipients of allo-
geneic hematopoietic cell transplantation is a prolonged
process that takes place over several years. Patients who
undergo transplantation at our facility are asked to return at
the one-year anniversary of their transplant for a compre-
hensive clinical and laboratory evaluation. We analyzed the
extent to which standard laboratory correlates of hemato-
logic and immune reconstitution at one year posttransplant
predict subsequent survival. Of 1273 patients with hemato-
logic malignancies who underwent their ﬁrst allogeneic
transplant between Jan. 1, 2001 and Dec. 31, 2010, and
survived at least one year, 875 returned for comprehensive
assessment at 12 +/- 2 months posttransplant and were
included in this retrospective study. Comparison of the
cohort of patients who returned for evaluation and those
who did not revealed no signiﬁcant differences save for
a larger proportion of patients (36.3 vs. 45.7%, p ¼ 0.002)
with high risk disease in the latter group. Patients were
classiﬁed by graft sources into 5 groups: matched related,
mismatched related, matched unrelated, mismatched unre-
lated, or unrelated cord blood (UCB). WBC, absolute
neutrophil, absolute lymphocyte, and platelet counts deter-
mined by automated cell counter were available for all
returning patients. Absolute CD4+, CD8+, CD19+, and CD56+
cell counts determined by ﬂow cytometry, and serum IgG
and IgA levels, were available for 405, 406, 389, 393, 866 and
732 patients, respectively. CD4+ lymphocytopenia at one-
year posttransplant was extremely common in all groups.
Reconstitution of CD19+ and CD56+ cells in the UCB group
was marginally better than in the other groups. However,
there were no signiﬁcant differences in the reconstitution of
CD4+ and CD8+ cells counts and serum IgG and IgA levels
according to graft sources. To determine whether any of the
common laboratory measures of immune reconstitution
observed at one year posttransplant were correlated with
subsequent survival, we conducted landmark analyses in
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210 S205which the patients were divided into quartiles according to
their hematologic and immunologic indices. WBC and
absolute neutrophil counts were not closely correlated with
subsequent survival. Patients in the lowest quartile of the
absolute lymphocyte and platelet count distributions,
however, experienced signiﬁcantly inferior survival beyond
one year (p¼0.012 and<0.001, respectively) when compared
with patients in the highest quartile (reference group).
Patients in the lowest quartiles of the absolute CD4+, CD19+,
CD56+, and serum IgG distributions also experienced signif-
icantly inferior survival (p¼0.019, 0.001, 0.02, and 0.023,
respectively). These results demonstrate that poor CD19+ B
cell recovery at 1 year is associatedwith inferior survival, and
suggest that interventions aimed at enhancing B cell recon-
stitution may have clinical beneﬁt.184
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Allogeneic stem cell transplant (ASCT) is a life saving
procedure for children with diverse malignant and non-
malignant conditions. The conditioning regimen renders the
patient very susceptible to infection until neutrophil (PMN)
engraftment occurs. In pediatric patients is not known if
these newly engrafted PMN's function normally, nor is it
known how long they take to become fully functional. We
hypothesize that pediatric patients, like their adult coun-
terparts, demonstrate PMN dysfunction at the time of
engraftment and beyond, which will be inﬂuenced by, the
conditioning regimen, stem cell source and level of GVHD,
and may predispose these children to serious bacterial and
fungal infections. Peripheral blood specimens were collected
from pediatric patients at Children's Hospital Colorado at 1, 2,
3, and 6 and 12months post ASCT. PMN's were isolated using
standard technique of ﬁcoll gradient, followed by hypotonic
lysis. PMN activity was assessed looking at 1) superoxide (02- )
production (luminescence); 2) azurophilic granule release
(colorimetric assay for elastase); 3) secondary granule
production (lactoferrin ELISA); 4) CD11b surface expression
(ﬂow cytometry), and; 5) phagocytosis (PhagotestTM-a ﬂow
cytometry assay).
Results: To date 22 patients have been enrolled; and over 50
samples obtained out to the 6 month post ASCT, with many
approaching 12 months post ASCT. Mean age of the partici-
pants is 10.8 years, and 65% aremale. Engraftment period has
averaged 24 days. Transplant types include eleven cord
bloods, six matched-related bone marrow donors, and three
matched-unrelated bone marrow donors. PMN function
appears to be relatively intact with no signiﬁcant differences
noted between healthy controls and sample specimens at all
time points in relation to 02- production, phagocytosis, CD11b
surface expression and lactoferrin. The lone exception is with
elastase release which is signiﬁcantly decreased at all time
points versus controls (P < .05); with a slow improvement
seen over time (Figure 1). Subgroup analysis did not show
a preferential difference in elastase release in relation to
speciﬁc stem cell source or conditioning regimen. We
conclude that similar to adults, pediatric patients have PMN
dysfunctionwhich appears to be restricted to elastase release
and continues 6 months post ASCT. A defect of this type is
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Stem cell transplantation (SCT) is the only curative
option for patients (pts) with Severe combined immuno-
deﬁciency (SCID). Adequate T cell function is usually ach-
ieved in these pts after SCT. Unfortunately, however,
adequate B cell function often fails, and little is known
about how disease type, conditioning or stem cell graft
inﬂuence this process. We report B cell function reconsti-
tution following SCT (1998-2012) in 35 SCID pts: IL2RG
(n¼13), JAK3 (n¼2), RAG1, 2 (n¼2), IL7RA (n¼5), CD3D
(n¼4), Zap70 (n¼2), MHCII def (n¼1), ADA (n¼2), and not
differentiated (n¼4). Fourteen pts received a haploidentical
donor graft, 8 pts a matched related donor (MRD) graft, 7
pts a matched/mismatched unrelated donor (MUD/MMUD)
graft, and 7 pts a mismatched unrelated cord blood
(MMUCB) graft. One pt received a MMUCB after a hap-
loidentical graft failure. 23 pts underwent ablative condi-
tioning with busulfan, cyclophosphamide, and ﬂudarabine
or cytarabine, 7 pts a reduced intensity conditioning using
ﬂudarabine and anti-CD52 and/or anti-CD45. Five pts were
not conditioned. Anti-CD52 was used in 22 pts. MMUCB
recipients receive no serotherapy. Overall survival of the
entire cohort was 87% with a median follow up of 6 years
(range, 0.5 -13 years); MRD and MMUCB graft recipients
had a 100% survival. To determine functional B cell
engraftment we measured IgA and total IgG. Engraftment
was considered successful when IgA was normal and levels
of IgG were above 500 mg/dL without supplemental IVIG.
Adequate B cell function of the whole group occurred at
a median time of 4 years (range, 2-13 years) in the hap-
loidentical and MRD recipients, at 3 years (range, 2-6 years)
in the MUD/MMUD recipients and at just 6 months (range,
4-11 months) in the MMUCB recipients. Five of 28 evalu-
able patients (3/14 haplo and 2/8 MUD) failed to achieve
